Clinical Trials Logo

Filter by:
NCT ID: NCT03534921 Completed - Clinical trials for Diabetes Mellitus, Type 2

Improving Diabetes Outcomes for People With Severe Mental Illness (SMI)

EMERALD
Start date: April 1, 2018
Phase:
Study type: Observational

This study aims to identify the determinants of diabetes and to explore variation in diabetes outcomes for people with severe mental illness (schizophrenia, schizoaffective disorder and bipolar disorder) in order to develop potential healthcare interventions that can be tested further. The study utilises a mixed methods design comprising analysis of patient primary care records and interviews with patients living with comorbid SMI and diabetes, family carers and healthcare professionals involved in commissioning or delivering healthcare for this population. This entry on the Protocol Registration and Results System describes only the quantitative Work Package of the study in detail i.e. analysis of patient primary care records.

NCT ID: NCT03534154 Completed - Clinical trials for Traumatic Brain Injury

Developing and Validating Blood and Imaging BIOmarkers of AXonal Injury Following Traumatic Brain Injury

BIO-AX-TBI
Start date: November 30, 2017
Phase:
Study type: Observational

Observational longitudinal study assessing outcomes following moderate-severe traumatic brain injury (TBI).

NCT ID: NCT03533751 Completed - Atopic Dermatitis Clinical Trials

Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

ATLAS
Start date: June 19, 2018
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profiles of multiple doses of etokimab in adult participants with atopic dermatitis (AD).

NCT ID: NCT03533114 Completed - Clinical trials for Idiopathic Hypersomnia

A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

Start date: November 27, 2018
Phase: Phase 3
Study type: Interventional

This is a study of the efficacy and safety of JZP-258, an oxybate mixed-salts oral solution being developed as a low sodium alternative product for Xyrem.

NCT ID: NCT03532906 Completed - Postoperative Pain Clinical Trials

Feasibility Study on Pain Control After Laparoscopic Cholecystectomy

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

The objective of the study is to hopefully understand the most beneficial way to control pain after removing the gallbladder by keyhole surgery (laparoscopic cholecystectomy). The investigators will investigate two groups of patients undergoing laparoscopic cholecystectomy. One group will receive the injection of local anaesthetic into the abdominal wall (TAP block) and into the wounds; the second group will have local anaesthetic into the wounds only. In order to have meaningful results, we anticipate a large number of participants would be required. Therefore we would test first whether it is technically possible to set up the study itself. The investigators will be looking at parameters (willingness of patients to be recruited, willingness of clinicians to recruit participants, number of eligible patients, follow-up rates, adherence/compliance rates, number of participants needed for an adequate sample size) that will allow to understand if such a larger trial is technically possible to set up.

NCT ID: NCT03532594 Completed - Clinical trials for Cardiovascular Diseases

Algorithmic Protamine Dosing for Reversal of Heparin After Cardiopulmonary Bypass

PRODOSE
Start date: April 16, 2018
Phase: N/A
Study type: Interventional

The PRODOSE trial is investigating a bespoke pharmacokinetic algorithm that calculates a tailored dose of protamine, required after cardiopulmonary bypass to reverse the action of heparin, based on individual patients and their actual bypass time. The PRODOSE trial aims to demonstrate that the algorithm can be used to define a protamine dose that will more reliably return coagulation parameters to pre-heparin levels as well as decreasing the risk of post-operative bleeding and transfusion. The trial aims to recruit 200 patients who will be randomised to either a bespoke or standard dose of protamine. The randomisation ratio will be 1:1 in the first instance but the trial uses an adaptive design and an interim analysis will be conducted after 100 patients have been randomised. The randomisation ratio could then be updated after the interim analysis to favour a superior arm whilst preserving statistical power levels.

NCT ID: NCT03532347 Completed - Pancreas Cancer Clinical Trials

Endoscopic Ultrasound Guided Tissue Sampling (The SharkBITE Study)

SharkBITE
Start date: May 22, 2017
Phase: N/A
Study type: Interventional

This study compares the diagnostic performance of Endoscopic ultrasound (EUS) guided fine needle aspiration and EUS guided core biopsy (SharkCore) in patients with a solid pancreatic mass.

NCT ID: NCT03531671 Completed - Cataract Clinical Trials

Assessing the Optics of the Eye Pre- and Post-operatively in Cataract

CAT
Start date: August 30, 2018
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate if a novel instrument called a Binocular Optical Coherence Tomographer (OCT) may resolve many of the issues with the assessment of patients with cataract.

NCT ID: NCT03531398 Completed - Nutrition Clinical Trials

Postprandial Responses to Typical UK Meal Nutrient Profiles

Pre-PREDICT
Start date: April 1, 2018
Phase: N/A
Study type: Interventional

The aim of the current study is to investigate the postprandial metabolic response to typically consumed fat and carbohydrate doses in single meals. An additional aim is to validate the use of dry blood spot (DBS) for triglyceride analysis versus venous blood sampling.

NCT ID: NCT03531229 Completed - Healthy Clinical Trials

Single Ascending Dose Study of Lu AF76432 in Healthy Young Men

Start date: April 17, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate safety, tolerability and pharmacokinetics of the drug Lu AF76432 given as single oral ascending doses to healthy young men